Back to Peptide Database
DermatologyInvestigational

Argireline (Acetyl Hexapeptide-8)

Overview

Argireline is a synthetic six amino acid peptide (Ac-Glu-Glu-Met-Gln-Arg-Arg-NH2) designed to attenuate neurotransmitter release at the neuromuscular junction. It functions as a competitive inhibitor of the SNARE complex, reducing catecholamine release and potentially diminishing muscle contraction intensity in facial expression muscles. This mechanism provides a topical alternative rationale to botulinum toxin for addressing expression lines, though with markedly lower potency.

Key Research Findings

In vitro studies have shown that acetyl hexapeptide-8 can inhibit SNARE complex formation in cell-free systems. Small cosmetic trials have reported modest reductions in periorbital wrinkle depth with twice-daily topical application over 30 days, though methodological rigor and independent replication remain limited. No peer-reviewed clinical trials in dermatology journals have established standardized efficacy benchmarks.

Route of Administration

Topical

Regulatory Status

Investigational

Interested in Argireline (Acetyl Hexapeptide-8)?

Find a verified provider experienced with Argireline (Acetyl Hexapeptide-8) protocols in your area. All providers are credentialed and use compliant sourcing.

Find a Argireline (Acetyl Hexapeptide-8) Provider

Related Peptides

Afamelanotide (Scenesse)

FDA Approved

A synthetic 13-amino acid analog of alpha-melanocyte-stimulating hormone (alpha-MSH) with a substitution of norleucine at position 4 that confers enhanced potency and enzymatic stability. Afamelanotide activates melanocortin-1 receptors (MC1R) on melanocytes, stimulating eumelanin production independent of UV exposure. The resulting increase in skin eumelanin provides photoprotection by absorbing UV radiation and scavenging reactive oxygen species.

Matrixyl (Palmitoyl Pentapeptide-4)

Investigational

Matrixyl is a lipopeptide composed of a pentapeptide sequence (Lys-Thr-Thr-Lys-Ser) attached to a palmitic acid moiety to enhance dermal penetration. It is proposed to stimulate fibroblast activity and upregulate synthesis of extracellular matrix components including collagen types I and III, fibronectin, and hyaluronic acid. The peptide serves as a matrikine fragment mimetic, signaling tissue remodeling pathways in aged or photodamaged skin.

Matrixyl 3000

Investigational

Matrixyl 3000 is a proprietary combination of two lipopeptides: palmitoyl tripeptide-1 (Pal-GHK) and palmitoyl tetrapeptide-7 (Pal-GQPR). The formulation is designed to synergistically promote collagen and fibronectin synthesis while reducing interleukin-6 mediated inflammation in dermal fibroblasts. Both peptides carry palmitic acid for enhanced lipid solubility and stratum corneum permeation.

Matrixyl Synthe'6 (Palmitoyl Tripeptide-38)

Investigational

Palmitoyl tripeptide-38 is a synthetic lipopeptide designed to stimulate synthesis of six major constituents of the dermal matrix: collagen I, III, and IV, fibronectin, hyaluronic acid, and laminin 5. It is proposed to activate transforming growth factor beta (TGF-beta) signaling in fibroblasts, thereby promoting coordinated extracellular matrix assembly. The palmitic acid conjugate enhances dermal bioavailability when applied topically.